On February 8, 2023, the Board of Directors of Compass Therapeutics, Inc. approved the appointment of a new director to its Board: David Wurzer, CPA, CFO of Enko Chem, Inc. The Board, upon recommendation of its Nominating and Corporate Governance Committee, appointed Mr. Wurzer as a Class III director, effective immediately to fill a vacant Class III Board seat, with a term expiring at the Company's annual meeting of stockholders in 2023. Mr. Wurzer was also appointed to serve as a member and chairman of the Company's Audit Committee. The Board determined that Mr. Wurzer is an independent director and meets the requirements of “audit committee financial expert” status under the Company's corporate governance guidelines and applicable Nasdaq Listing Rules.